Ambulatory use of olanzapine and risperidone:: A population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia

被引:27
作者
Cooper, D
Moisan, J
Gaudet, M
Abdous, B
Grégoire, JP
机构
[1] Univ Quebec, Dept Med Sociale & Prevent, Ctr Hosp, Quebec City, PQ, Canada
[2] Univ Laval, Fac Pharm, Quebec City, PQ, Canada
[3] Univ Quebec, Unite Rech Sante Populat, Ctr Hosp, Quebec City, PQ, Canada
[4] Univ Laval, Unite Rech Sante Populat, Quebec City, PQ, Canada
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 2005年 / 50卷 / 14期
关键词
atypical antipsychotics; schizophrenia; persistence; concomitant therapy; prescription drug databases; cohort studies;
D O I
10.1177/070674370505001404
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To assess treatment discontinuation and concomitant use of other antipsychotics among individuals initiated on olanzapine or risperidone for the treatment of schizophrenia. Method: Using data from the Quebec health insurance plan and the Quebec database for hospitalization, we conducted a population-based cohort study of patients for whom a first claim for olanzapine or risperidone was submitted between 1 January 1997 and 31 August 1999. Included were 6405 patients with schizophrenia whom we followed from the date of the first claim for olanzapine or risperidone either to discontinuation date, end of eligibility for the drug plan, 365 days, date of moving out of the province, or date of death. We used Cox regression models to compute hazards ratios (HRs) of having the treatment discontinued and logistic regression models to compute odds ratios (ORs) among persisting patients of having any concomitant antipsychotic prescription. All models were adjusted for age, sex, schizophrenia disorder, corriorbidity, region, beneficiary type, substance use disorder, and prior hospitalization for mental illness. Results: Compared with risperidone users (n = 2718), discontinuation rates were lower for olanzapine users (n = 3687; HR = 0.79; 95%Cl, 0.74 to 0.84). The odds of receiving any concomitant antipsychotic prescription did not differ statistically between olanzapine and risperidone users (OR 0.85; 95%Cl, 0.71 to 1.01). Conclusions: The study results suggest that new users of olanzapine were less likely to discontinue their initial treatment than were new users of risperidone, although discontinuation was high in both groups. Among those who persisted, concomitant use of other antipsychotics did not differ between olanzapine users and risperidone users.
引用
收藏
页码:901 / 908
页数:8
相关论文
共 27 条
[21]  
Stahl SM, 1999, J CLIN PSYCHIAT, V60, P31
[22]   Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? [J].
Stahl, SM .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :425-426
[23]   THE USE OF PRESCRIPTION CLAIMS DATABASES IN PHARMACOEPIDEMIOLOGIC RESEARCH - THE ACCURACY AND COMPREHENSIVENESS OF THE PRESCRIPTION CLAIMS DATABASE IN QUEBEC [J].
TAMBLYN, R ;
LAVOIE, G ;
PETRELLA, L ;
MONETTE, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (08) :999-1009
[24]   Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder [J].
Volavka, J ;
Czobor, P ;
Sheitman, B ;
Lindenmayer, JP ;
Citrome, L ;
McEvoy, JP ;
Cooper, TB ;
Chakos, M ;
Lieberman, JA .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (02) :255-262
[25]   A CHRONIC DISEASE SCORE FROM AUTOMATED PHARMACY DATA [J].
VONKORFF, M ;
WAGNER, EH ;
SAUNDERS, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (02) :197-203
[26]   Dropout rates in randomised antipsychotic drug trials [J].
Wahlbeck, K ;
Tuunainen, A ;
Ahokas, A ;
Leucht, S .
PSYCHOPHARMACOLOGY, 2001, 155 (03) :230-233
[27]   COST OF RELAPSE IN SCHIZOPHRENIA [J].
WEIDEN, PJ ;
OLFSON, M .
SCHIZOPHRENIA BULLETIN, 1995, 21 (03) :419-429